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Angiographic eb try criteria included the presence of 21 stenosis 250% in a major epicardial coronary artery, and certiication of film quality through the core an@-ography laboratory. Patients qualified for random ixation if after diet stabilization their low density lipoprotein cholesterol concentrations were 2130 and cl90 mg/dl, and triglycerides were 1350 mg/dl. Pravastatin (40 mg) or placebo is adminis tered once daily at bedtime. Arteriography will be repeated at the end of 3 years of treatment. The primary end point of the study is the change in * solute mean coronary artery diameter. During a 99month recruitment period, 44,145 patients were screened, and 408 were randomized. The most frequent reason for excludi* patients dulc ing the screenhtg and dietary lea&in periods was a low senun cholesterol level. A large proportion of patients with documented coronary artery di+ ease have cholesterol concentrations that are considered to be normal or only modestly iu creased. Adherence to strict standards of quality control for di@tal analysis of angiograms ensures that baseline anfgograms can be interpreted at the end of Syear follow-up.
(Am J Cardiol1993;72:31-35) P onary Arteries (PLAC I) is a multicenter, prospective, randomized, placebo-controlled trial of the effect of lipid-altering therapy on the progression of coronary artery disease. The study was designed with 2 goals: The lirst was to evaluate the effects of monotherapy with pravastatin, a hydrophilic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on progression and regression of coronary artery disease measured by quantitative angiography. The second goal was to evaluate progression and regression of atherosclerosis in patients with only moderate increases of low-density lipoprotein (LDL) cholesterol, typical of those with symptomatic coronary artery disease. This article describes the protocol design and recruiting experience.
METHODS
The protocol was approved by the institutional review board at each study site. All patients gave written, informed consent to participate in the trial. The study was initiated in early 1988, and randomization ended after a 30-month recruitment period. All follow-up angiography will be completed in the spring of 1993.
5creening an@ography: At each site (see Appendix), all patients undergoing clinically indicated coronary arteriography were screened for eligibility. The protocol for angiography required 22 orthogonal or nearorthogonal views of all coronary segments, central placement of the catheter (>5Fr) in the radiographic image, administration of nitroglycerin before injection of contrast medium (in the absence of contraindications), and detailed documentation of the sequence of injections during the procedure, including the angles of view.
A patient had to have 21 stenosis 250% in a major epicardial coronary artery to qualify for the study. The protocol required review of the documentation of the procedure, presence of an adequate portion of the angiographic catheter in a central portion of the image, digitization of eligible angiographic segments, and exclusion of excessive contrast streaming. A previously described and validated quantitative coronary artery evaluation method was used to analyze all focal stenoses in any study segment. l Dietary stabilization/qualiication for randomizk+ tion: Patients who fulfilled the initial screening criteria were referred to a dietitian for instruction in a fat-restricted, low-cholesterol diet (American Heart Associa- despite treatment, or untreated 9. History of cerebrovascular disease 10. Gastrointestinal disease or surgery that may interfere with drug absorption 11. Alcohol consumption >3 drinks/day (1 drink = 1.5 oz of 80 proof liquor,'or equivalent) 12. Chronic pancreatitis 13. History of hypersensitivity to 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 14. Systemic lupus erythematosus tion Phase I or equivalent*). After 24 weeks of a stable diet, the lirst lipid prosle was determined; subsequent determinations were obtained at l-to 4-week intervals. To qualify for randomization, the average of 2 consecutive LDL cholesterol concentrations needed to be 2130 mg/dl (3.36 mmol/liter) but <190 mg/dl (4.91 mmol/ liter), and the average triglycerides 13.50 mg/dl (3.95 mmol/liter).
Other inclusion/exclusion criteria: Before enrollment in the study, patients had to consent to coronary arteriography again at the end of 3 years of treatment. Patients receiving treatment with lipid-lowering therapy could be enrolled if an appropriate drug washout period preceded the t&t qualifying lipid determination. Other exclusion criteria are listed in Table I .
Dtug m and Z&W&WOE Pravastatin or matching placebo (provided by the Bristol-Myers Squibb Pharmaceutical Research Institute) is administered as two 20 mg tablets at bedtime (40 mg total), and dosage remains lixed for the duration of the study unless safety considerations dictate a reduction. Assignment to placebo or active drug is balanced witbin strata defined by clinical characteristics (myocardial infarction, percutaneous transluminal coronary angioplasty and stable or unstable angina) and baseline LDL cholesterol concentration (130 to 169 and 170 to 189 mg/dl).
Over the course of a 3-year study, LDL cholesterol may be expected to increase to 2190 mg/dl, approximately the 90th percentile for the United States population in some patients. Because of the demonstrated benefits of treating patients with such marked cholesterol increase,3 care was taken to identify and treat them. If the mean of 3 consecutive LDL cholesterol levels is 2190 mg/dl in any patient, personnel at the site are to be notified in writing to advance the diet to the American Heart Association Phase II or equivalent diet.* To maintain study integrity and blinding, a patient from the other treatment group matched by age, sex and upper tertile of LDL cholesterol concentration is to be chosen to change diet also. If LDL cholesterol does not decrease to ~190 mgJll after 1 month, the patient and matching subject are to be instructed to begin taking cholestyramine resin beginning with 1 packet (bid) titrated to a maximum of 6 packets/day. Patients whose levels remain 2290 mg/dl despite addition of cholestyramine are to be administered 5 to 10 mg of open-label pravastatin (or placebo, depending on original treatment assignment). If these measures are unsuccessful, the patient is withdrawn from the study. Evaluatii of patients: Patients are to return to the clinic every 6 weeks for the first 18 months of the study for safety evaluation (liver-enzyme elevation and adverse events), and every 12 weeks thereafter. Follow-up arteriography is to be performed after 36 months, or earlier, if feasible, in the event of withdrawal from the study, or coronary artery bypass graft surgery. As each patient completes the study, the paired baseline and follow-up cineangiograms (blinded to order and patient identifcation) will be reviewed by an experienced angiographer who will select matching views for analysis. (The preliminary core laboratory reading will be used only for qualification of the Iilm.)
Interim monhing/polii advkwy bozd The conduct of the study is reviewed semiannually by a policy advisory board of 5 members (see Appendix) who are independent of the sponsor and trial organization.
. .
tmmh&ms/end point adysis plans:
Original sample-size calculations were based on the limited data then available on progression rates and variability from the Coronary Artery Surgery Study.4 A total sample size of 400 subjects was deemed adequate to demonstrate a 40% treatment effect. More recent quantitative data enable more accurate sample-size estimates5 Assuming a decrease in mean coronary artery diameter of 0.20 mm in the placebo group, an SD of 0.34 mm, 80% power and 0.05 significance level (Zsided), the detectable treatment effect ranges between 51 and 55% for 350 and 300 patients, respectively, completing the study (allowing for withdrawals).
The primary end point of the study is the rate of progression for mean diameter averaged over the following 10 segments: left main, proximal and mid-left anterior descending, largest diagonal, proximal and distal left circumllex, largest obtuse marginal, and proximal, midand distal right. Any angiogram obtained 290 days after initiation of double-blind therapy can be included in the analysis of the primary end point. The primary analysis will be by intention-to-treat. Rates of progression will by analyzed using rank-based tests (e.g., rank-sum tests) and expressed as a slope (mm/month). (This results in the variable being weighted for time on trial.) If a fmal angiogram is not available in a subject because of death or myocardial infarction, a value will be imputed for that patient equal to the greatest progression rate observed in the group completing 36 months in the trial, corrected for duration of follow-up. Arteries and segments that undergo angioplasty or coronary artery bypass graft will be excluded from the study. (Patients undergoing coronary artery surgery during the study will be delined as having reached a study end point, and the angiogram before surgery will be included in the analysis.)
Several secondary angiographic and lipoprotein end point analyses are planned (Table II) . Secondary clinical end points include occurrence of myocardial infarction, stroke, angioplasty and coronary artery bypass graft surgery, and total and cause-specific mortality.
RESULTS
Recruitment began in early 1988 and ended approximately 2.5 years later (Figure 1) . Tables III and IV list the reasons why patients were excluded during the screening and dietary lead-in periods. The most frequent reason for excluding a patient during the early screening phase was low serum cholesterol level. In general, subjects were enrolled in the dietary stabilization phase if the screening total cholesterol level was 2210 to 220 mg/dl, although there was considerable variation from site to site, and the threshold depended on whether a fatrestricted diet was already being followed. Based on the accumulating experience, several changes were made in the protocol and conduct of the study (including increas- ing the number of participating centers) to enable randomization to be completed successfully. The protocol revision having the greatest impact on enrollment was changing the lower limit required for mean LDL cholesterol from 150 to 130 mg/dl (Figure 1 ). This fmding provides additional support for the qualitative observation that most patients with coronary artery disease have only moderate increases of total and LDL cholesterol.
Other revisions with only modest effects on recruitment included increasing the upper age limit from 70 to 75 years, and the upper limit for triglycerides from 300 to 350 mg/dl, and allowing subjects with stable or un- stable angina (in addition to those after myocardial infarction or angioplasty) to participate in the study. Tables IlI and IV show that some patients were excluded from the study because either the angiographic protocol was not followed, or qualifying clinical or angiographic criteria were absent, or both. Some patients were included whose angiograms were sent for certification, but were not accepted after analysis in the core angiography laboratory. Table V shows the reasons for rejecting these films. The overall acceptance rate was 90.1% of submitted films. In contrast, in the early phases of the study, the acceptance rate was as low as 71%. Protocol adherence and film quality improved after the reasons for rejection were reviewed with the clinical sites.
Baseline demographic characteristics of the 408 patients randomized are listed in Table VI. DISCUSSION PLAC I and other ongoing studies should help establish whether treatment of patients with moderately increased serum cholesterol levels slows progression of coronary artery disease and presumably prevents clinical events as much as in trials of those with severe hypercholesterolemia. 6,7 The positive or negative results should have important implications for the large number of patients with coronary artery disease but only moderate LDL cholesterol elevation.
Several features of the design and recruitment of patients in the trial deserve comment, and may bear on the design of future studies. Assessment of the progression of coronary artery disease was the primary aim. Thus, before randomization, each patient's angiogram was screened through the core angiography laboratory to ensure that the protocol was followed and that the angiogram could be sufficiently digitized to ensure adequate analysis at the end of 3-year follow-up. In the early phases of the study, >lOO angiographers were participating, and variation in attention to contrast streaming and protocol adherence was considerable. After core laboratory personnel rejected several lihns, protocol adherence improved substantially. Table V The most frequent reason for excluding patients from the study was low serum cholesterol (Table BI) . A large proportion of patients with documented coronary artery disease have cholesterol concentrations only modestly increased or within the range considered normal for the U.S. population. The data support conclusions from other studies8,9 and have important implications not only for future trials but also for understanding the pathogenesis of coronary artery disease. Mechanisms other than hyperlipidemia, such as insulin resistance, may be of substantial pathophysiologic importance in patients with only moderate or no increase in serum LDL cholesterol. Although a lipid-lowering strategy such as monotherapy with pravastatin is likely to benefit patients with severe or moderately severe hypercholesterolemia, the effect of reducing lipids in those with only minimal or no increase in serum lipids despite coronary artery disease should be determined. 
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